ClinicalTrials.gg
CompletedNCT05002270Updated Jan 13, 2026

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

A Phase 1/2 interventional study of JAB-21822 (KRAS G12C inhibitor) and JAB-21822 (KRAS G12C inhibitor) in Advanced Solid Tumor, NSCLC and CRC, sponsored by Jacobio Pharmaceuticals Co., Ltd.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Jacobio Pharmaceuticals Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
2,055th of 2,995
29 · median 56
Started
2021
with 181 others
Phase 1/2
484 of 3,368
117 open now
Registered
2,558th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 2,055th largest by enrollment of the 2,995 interventional ones that give a count, is one of 182 that started in 2021, is one of 484 in phase 1/2, and was the 2,558th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

Read the detailed description

The primary objective of this study is to evaluate the safety and tolerability of JAB-21822 monotherapy to determine the MTD and PR2D during Dose Escalation phase; then to evaluate preliminary antitumor activity when JAB-21822 administered alone and combination with cetuximab during Dose Expansion phase in adult participants with advanced solid tumors harboring KRAS G12C mutation.

03

Conditions studied

  • Advanced Solid Tumor
  • NSCLC
  • CRC

Keywords

  • KRAS G12C Mutant Advanced Solid Tumor; NSCLC; CRC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to provide an archived tumor sample
  • or cytologically confirmed solid tumors with KRAS G12C mutation
  • Must have received at least 1 prior standard therapy
  • Must have at least 1 per v1.1
  • Must have adequate organ function
  • Must be able to swallow and retain orally administered medication

Exclusion criteria

Exclusion Criteria:

  • Has brain or spinal , except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days
  • Active infection requiring systemic treatment within 7 days
  • Active or
  • Any severe and/or uncontrolled medical conditions
  • ≤50% assessed by ECHO or
  • QT interval >470 msec
  • Experiencing unresolved 5.0 Grade >1 toxicities
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Arm A0, JAB-21822 monotherapy, Phase 1, Dose Escalation

    Dose escalation of JAB-21822 will be administered alone to determine the MTD and RP2D

    Drug: JAB-21822 (KRAS G12C inhibitor)

  • Experimental
    Arm A1, JAB-21822 monotherapy, Phare 2, Dose Expansion

    JAB-21822 will be administered alone at RP2D in selected cancer type patients to evaluate the preliminary antitumor activity.

    Drug: JAB-21822 (KRAS G12C inhibitor)

  • Experimental
    Experimental: Arm B, JAB-21822 combination with Cetuximab, Phase 2, Dose Expansion

    JAB-21822 will be administered together with Cetuximab in mCRC patients to evaluate the preliminary antitumor activity.

    Drug: JAB-21822 (KRAS G12C inhibitor) · Drug: Cetuximab (EGFR inhibitor)

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  2. Dose Escalation and Dose Expansion phase: Number of participants with adverse events

    Patients will be assessed for incidence and severity of adverse events (AEs) according to NCI-CTCAE criteria

    Time frame: Up to 4 years

  3. Dose Expansion phase: Overall response rate (ORR)

    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) per RECIST v 1.1

    Time frame: Up to 4 years - from baseline to RECIST confirmed Progressive Disease

  4. Dose Expansion phase: Duration of response ( DOR )

    DOR is defined as the time from the participant's initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to 4 years

Secondary outcomes

  1. Dose Escalation and Dose Expansion phase: Peak Plasma Concentration (Cmax)

    Cmax of JAB-21822 alone or JAB-21822 plus cetuximabn will be measured by using plasma PK samples

    Time frame: Up to 4 years

  2. Dose Escalation and Dose Expansion phase: Area under the plasma concentration versus time curve (AUC)

    AUC of JAB-21822 alone or JAB-21822 plus cetuximab will be measured by using plasma PK samples

    Time frame: Up to 4 years

  3. Dose Escalation phase: Overall response rate (ORR)

    The percentage of participants with complete response (CR) or partial response (PR) on RECIST v 1.1.

    Time frame: Up to 4 years - from baseline to RECIST confirmed Progressive Disease

  4. Dose Escalation phase: Duration of response ( DOR )

    DOR is defined as the time from the participant's initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to 4 years

  5. Dose Escalation and Dose Expansion phase: Disease Control Rate ( DCR )

    DCR is defined as percentage of participants with complete response (CR), partial response (PR), or stable disease(SD) per CTCAE v1.1

    Time frame: Up to 4 years

  6. Dose Escalation and Dose Expansion phase: Progression-free survival (PFS)

    PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression per CTCAE v1.1 or death which occurs first

    Time frame: Up to 4 years

07

Study locations

4 sites
  • Mayo Clinc
    Phoenix, Arizona 85054, United States
  • Mayo Clinc
    Scottsdale, Arizona 85259, United States
  • Mayo Clinc
    Jacksonville, Florida 32224, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
08

References and documents

Publications

  • Li J, Deng T, Gu Y, Calles Blanco A, Li Z, Bai C, Wu L, Huang J, Li X, Yao Y, Song Z, Li Y, Liu L, Xing L, Wu W, Martinez-Perez J, Hubert A, Zugazagoitia J, Zhang J, Wang Y, Zhao Y, Wen G, Xia G, Zhong D, Chen X, Jiang K, Wang-Gillam A, Ding Y, Liu S, Rao Z, Liu X, Shen L. Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials. Cancer Commun (Lond). 2025 Nov;45(11):1500-1512. doi: 10.1002/cac2.70056. Epub 2025 Oct 2. PubMed 41037823 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Feb 2025, 41 months.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 41 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2021
First posted
Aug 12, 2021
StartActual
Sep 3, 2021
Primary completionActual
Feb 12, 2025
CompletionActual
Feb 12, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05002270
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Sep 3, 2021
Primary completion
Feb 12, 2025
Completion
Feb 12, 2025
Last update
Jan 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glecirasib

Start the discussion